Technical Analysis for AEZS - AEterna Zentaris Inc.

Grade Last Price % Change Price Change
grade D 3.05 -1.61% -0.05
AEZS closed down 1.61 percent on Thursday, April 27, 2017, on 77 percent of normal volume. It was able to find support at its 50 day moving average. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Earnings due: May 8

Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical AEZS trend table...

Date Alert Name Type % Chg
Apr 27 50 DMA Support Bullish 0.00%
Apr 27 Bollinger Band Squeeze Range Contraction 0.00%
Apr 27 Upper Bollinger Band Walk Other 0.00%
Apr 26 Stochastic Reached Overbought Other -1.61%
Apr 26 Bollinger Band Squeeze Range Contraction -1.61%
Apr 25 50 DMA Support Bullish -1.61%
Apr 25 Doji - Bearish? Reversal -1.61%
Apr 25 Bollinger Band Squeeze Range Contraction -1.61%
Apr 24 Crossed Above 50 DMA Bullish 0.00%
Apr 24 Bollinger Band Squeeze Range Contraction 0.00%

Older signals for AEZS ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Basic chart:

Aeterna Zentaris Inc. a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for oncology and endocrine therapy primarily in Switzerland, the United States, and Japan. It markets Cetrotide, a luteinizing hormone-releasing hormone antagonist treatment for in vitro fertilization. The company’s product pipeline includes AEZS-108, which is in Phase III clinical trial for the treatment of endometrial cancer, as well as in Phase II clinical trial to treat triple-negative breast, ovarian, castration and taxane resistant prostate, and refractory bladder cancers; and AEZS-130, an oral diagnostic test that has completed Phase III clinical trial for adult growth hormone deficiency, as well as in Phase IIA clinical trial for the treatment of cancer-induced cachexia. Its product pipeline also comprise Ozarelix, which is in Phase II clinical trial for the treatment of prostate cancer; Perifosine that is in Phase I/II clinical trials for the treatment of neuroblastoma, glioma, and pediatric solid tumors; and AEZS-112 an oral anticancer agent, which has completed Phase I clinical trial for the treatment of solid tumors and lymphoma. In addition, the company’s products in preclinical development consist of AEZS-120, a live recombinant oral tumor vaccine candidate for the treatment of prostate cancer; AEZS-129, 134, and 136 PI3K/Erk inhibitors for oncology; and AEZS-137 and AEZS-125 for oncology. Aeterna Zentaris Inc. was founded in 1990 and is headquartered in Quebec City, Canada.
Is AEZS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 5.59
52 Week Low 2.35
Average Volume 166,396
200-Day Moving Average 3.3565
50-Day Moving Average 3.0115
20-Day Moving Average 2.9888
10-Day Moving Average 2.9975
Average True Range 0.152
ADX 10.25
+DI 19.16
-DI: 18.22
Chandelier Exit (Long, 3 ATRs) 2.794
Chandelier Exit (Short, 3 ATRs) 3.206
Upper Bollinger Band 3.1253
Lower Bollinger Band 2.8523
Percent B (%b) 0.72
Bandwidth 0.091341